Abstract
The article presents the results of the study of clinical efficacy of treatment of acute rhinosinusitis in 80 children aged 3–15 years using Sialor® as an adjunct to comprehensive treatment. The children of group 1 (active treatment group) received Sialor® in addition to the standard treatment without use of decongestants. group 2 (comparison group) received decongestants in addition to the standard treatment without use of Sialor®. The efficacy of treatment was assessed according to clinical examination findings. The study showed that the inclusion of Sialor® (silver proteinate) in the combined treatment improves the clinical efficacy of treatment of acute rhinosinusitis. On Day 4 after the first examination, group I showed a decrease in nasal congestion that was evaluated using Visual Analogue Scale (VAS) by more than 4 points as compared with group 2. On Day 4 of treatment, presentations of rhinorrhea in the active treatment group of children decreased by more than 2 points on VAS scale compared with the control group. The children who received Sialor also demonstrated an improvement in the quality of sleep. The results showed that the inclusion of Sialor (silver proteinate) in the treatment regimen of ARS allows to achieve a more rapid relief of symptoms of intoxication, nasal congestion, rhinorrhea, restoration of smell, improvement in the quality of sleep of patients by Day 4 from the start of treatment.
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.